Treatment of Refractory Pityriasis Rubra Pilaris with Novel Phosphodiesterase 4

Total Page:16

File Type:pdf, Size:1020Kb

Treatment of Refractory Pityriasis Rubra Pilaris with Novel Phosphodiesterase 4 Letters Discussion | Acrodermatitis continua of Hallopeau, also Additional Contributions: We thank the patient for granting permission to known as acrodermatitis perstans and dermatitis repens, publish this information. is a rare inflammatory pustular dermatosis of the distal fin- 1. Saunier J, Debarbieux S, Jullien D, Garnier L, Dalle S, Thomas L. Acrodermatitis continua of Hallopeau treated successfully with ustekinumab gers and toes. It is considered a variant of pustular psoriasis and acitretin after failure of tumour necrosis factor blockade and anakinra. or, less commonly, its own pustular psoriasis-like indepen- Dermatology. 2015;230(2):97-100. 1 dent entity. Precise pathophysiology and incidence 2. Kiszewski AE, De Villa D, Scheibel I, Ricachnevsky N. An infant with are unknown. Case literature suggests predominance in acrodermatitis continua of Hallopeau: successful treatment with thalidomide women, but the disease affects both sexes and, rarely, and UVB therapy. Pediatr Dermatol. 2009;26(1):105-106. children.2 3. Jo SJ, Park JY, Yoon HS, Youn JI. Case of acrodermatitis continua accompanied by psoriatic arthritis. J Dermatol. 2006;33(11):787-791. Acrodermatitis continua of Hallopeau initially presents 4. Sehgal VN, Verma P, Sharma S, et al. Acrodermatitis continua of Hallopeau: as erythema overlying the distal digits that evolves into evolution of treatment options. Int J Dermatol. 2011;50(10):1195-1211. pustules.2 The nail bed is often involved, with paronychial 5. Lutz V, Lipsker D. Acitretin- and tumor necrosis factor inhibitor-resistant 3 and subungual involvement and atrophic skin changes. acrodermatitis continua of Hallopeau responsive to the interleukin 1 receptor Most patients experience a chronic, relapsing course involv- antagonist anakinra. Arch Dermatol. 2012;148(3):297-299. ing the proximal digit as the condition worsens.4 Acroder- 6. Iborra M, Beltrán B, Bastida G, Aguas M, Nos P. Infliximab and matitis continua of Hallopeau has been reported to both adalimumab-induced psoriasis in Crohn’s disease: a paradoxical side effect. J Crohns Colitis. 2011;5(2):157-161. evolve into and stem from generalized plaque or pustular psoriasis.3 The present patient was noted to have plaque psoriasis lesions nearly 1 year after the onset of her disease. Treatment of Refractory Pityriasis Rubra Pilaris Psoriatic arthritis is a rare complication,3 but distal phalanx With Novel Phosphodiesterase 4 (PDE4) Inhibitor osteolysis is an important comorbidity.1 Apremilast The differential diagnosis includes infectious paro- Pityriasis rubra pilaris (PRP) is an inflammatory dermato- nychia of viral, fungal, or bacterial etiology, infected contact logic disorder of unknown cause characterized by hyper- dermatitis, and dyshidrotic eczema.4 Gram stain, potassium keratotic follicular papules combining into salmon-colored hydroxide mount, culture, and microscopy may be useful in scaling plaques, palmoplantar hyperkeratosis, and sharply diagnosis. Histopathologically, ACH is characterized by demarcated islands of spared skin.1 We report a case neutrophil-rich spongiform pustules within the epidermis, of refractory PRP treated with the immune modulator dermal edema, and lymphohistiocytosis.4 As in pustular apremilast. psoriasis, biopsy from the nail bed often reveals acanthosis and spongiform pustules.3 Report of a Case | A white man in his 70s presented with an Treatment with topical corticosteroids, tacrolimus, fluo- 8-month history of scaling, pink, pruritic papules, originat- rouracil, calcipotriol, methotrexate, acitretin, cyclosporine, and ing on his back (Figure, A), which coalesced to encompass phototherapy have produced inconsistent responses. Success- nearly his entire body surface. There was extensive ery- ful treatment with tumor necrosis factor inhibitors and the IL-1 thema with scaling and waxy, hyperkeratotic scaling of inhibitor anakinra5 have been reported. However, these agents the palms and soles. are not always efficacious and may even have the potential to A punch biopsy was performed for hematoxylin-eosin incite pustular psoriasis.6 staining and demonstrated alternating parakeratosis and Two cases of ACH treated with concomitant ustekinumab orthokeratosis with spongiosis and mild superficial lympho- and acitretin have been reported, one successfully,1 the other cytic infiltrate. Given these findings, PRP was diagnosed. unsuccessfully.5 The present case is the first to our knowl- The patient started acitretin therapy and showed initial im- edge to be successfully treated with ustekinumab as mono- provement, but after 4 months, his disease continued to prog- therapy. Given that the literature supports ustekinumab as ress. He was transitioned to methotrexate therapy with pred- monotherapy and concomitant therapy for pustular psoria- nisone bridging. However, the methotrexate regimen was sis, ustekinumab was a reasonable choice for our patient and discontinued after 8 weeks owing to lack of response and was succeeded when other agents had failed. replaced with cyclosporine. After 4 weeks of marginal re- sponse with cyclosporine and prednisone, infliximab was Rachel M. Cymerman, BA added, based on literature reports of improvement of PRP with David E. Cohen, MD tumor necrosis factor (TNF) inhibition.2,3 The patient showed marked improvement after 1 inflixi- Author Affiliations: The Ronald O. Perelman Department of Dermatology, mab infusion of 5mg/kg. Unfortunately, 4 weeks later, he was New York University School of Medicine, New York, New York. diagnosed with small-cell lymphocytic leukemia (SLL). Be- Corresponding Author: David E. Cohen, MD, The Ronald O. Perelman cause TNF inhibitors have been associated with an increased Department of Dermatology, New York University School of Medicine, 240 E risk of lymphoma,4 infliximab therapy was discontinued. The 38th St, 11th Floor, New York, NY 10016 ([email protected]). patient sought care for SLL, and rituximab and bendamus- Published Online: November 11, 2015. doi:10.1001/jamadermatol.2015.3444. tine chemotherapy was initiated. After completion of the Conflict of Interest Disclosures: Dr Cohen has consulted for Ferndale, chemotherapy, his PRP worsened. Galderma, and Medimetrics and owns stock or options in Dermira, Topica, and Medimetrics; none of these companies had any role in the present article. No The challenge was to identify a PRP-directed treatment other disclosures are reported. in a patient with refractory disease and contraindication to 348 JAMA Dermatology March 2016 Volume 152, Number 3 (Reprinted) jamadermatology.com Copyright 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Letters Figure. A Case of Refractory Pityriasis Rubra Pilaris Before and After 8 Months of Apremilast Therapy A Before treatment B After 8 months of treatment Almost complete resolution is seen on the back of this elderly male patient. TNF inhibitors. After exhausting therapeutic options, we TNF inhibition, the choice of apremilast was a logical next considered apremilast (Otezla; Celgene Corporation). The step for the patient in the present case. The drug is appeal- patient started with a dose of 10 mg/d and titrated over ing owing to its minimal adverse effects and monitoring 5 days to the recommended maintenance dose of 30 mg requirements.6 At 12-month follow-up, the patient twice daily. remained disease free. Four weeks later, the patient reported significant Our experience suggests that apremilast may be an improvement in symptoms. He complained of mild gastro- effective treatment for refractory PRP. Additional studies intestinal upset but denied other new symptoms. The most are necessary to further establish the role of PDE4 inhibitors common adverse effects reported with apremilast are diar- as an option for refractory PRP. rhea, nausea, and headache.5 At 8- and 12-week follow-ups, he reported further decreases in body surface area involve- Ifat Zerin Krase, PharmD ment of PRP. At 6- and 8-month follow-ups, he showed Kevin Cavanaugh, MD nearly complete resolution of skin findings (Figure, B). Clara Curiel-Lewandrowski, MD Discussion | There is no unifying etiology to the pathogenesis Author Affiliations: University of Arizona College of Medicine, Tucson (Krase); Department of Dermatology, University of Arizona, Tucson (Cavanaugh, of PRP. Current treatments are mainly empirical or based on Curiel-Lewandrowski). case reports. Systemic retinoids and methotrexate are often Corresponding Author: Clara Curiel-Lewandrowski, MD, Department of used as first-line treatments. Other therapies include aza- Dermatology, University of Arizona, 1501 N Campbell Ave, Tucson, AZ 85724 thioprine, cyclosporine, fumaric acid, mycophenolate ([email protected]). mofetil, vitamin D analogues, and phototherapy.1,2 Published Online: November 4, 2015. doi:10.1001/jamadermatol.2015.3405. Eastham et al3 demonstrated, in the most comprehen- Conflict of Interest Disclosures: None reported. sive analysis to date, that TNF inhibition is effective for re- Additional Contributions: We are indebted to Fangru Lian, MD, Department of fractory PRP. The patient in the present case responded well Pathology, University of Arizona, Tucson, for providing the histopathologic to infliximab but could not continue therapy because he analysis for the case. She did not receive any compensation for her developed SLL. Based on the proposed immune-driven contributions. mechanism of PRP, we explored novel treatments targeting 1. Klein A, Landthaler M, Karrer
Recommended publications
  • The Use of Biologic Agents in the Treatment of Oral Lesions Due to Pemphigus and Behçet's Disease: a Systematic Review
    Davis GE, Sarandev G, Vaughan AT, Al-Eryani K, Enciso R. The Use of Biologic Agents in the Treatment of Oral Lesions due to Pemphigus and Behçet’s Disease: A Systematic Review. J Anesthesiol & Pain Therapy. 2020;1(1):14-23 Systematic Review Open Access The Use of Biologic Agents in the Treatment of Oral Lesions due to Pemphigus and Behçet’s Disease: A Systematic Review Gerald E. Davis II1,2, George Sarandev1, Alexander T. Vaughan1, Kamal Al-Eryani3, Reyes Enciso4* 1Advanced graduate, Master of Science Program in Orofacial Pain and Oral Medicine, Herman Ostrow School of Dentistry of USC, Los Angeles, California, USA 2Assistant Dean of Academic Affairs, Assistant Professor, Restorative Dentistry, Meharry Medical College, School of Dentistry, Nashville, Tennessee, USA 3Assistant Professor of Clinical Dentistry, Division of Periodontology, Dental Hygiene & Diagnostic Sciences, Herman Ostrow School of Dentistry of USC, Los Angeles, California, USA 4Associate Professor (Instructional), Division of Dental Public Health and Pediatric Dentistry, Herman Ostrow School of Dentistry of USC, Los Angeles, California, USA Article Info Abstract Article Notes Background: Current treatments for pemphigus and Behçet’s disease, such Received: : March 11, 2019 as corticosteroids, have long-term serious adverse effects. Accepted: : April 29, 2020 Objective: The objective of this systematic review was to evaluate the *Correspondence: efficacy of biologic agents (biopharmaceuticals manufactured via a biological *Dr. Reyes Enciso, Associate Professor (Instructional), Division source) on the treatment of intraoral lesions associated with pemphigus and of Dental Public Health and Pediatric Dentistry, Herman Ostrow Behçet’s disease compared to glucocorticoids or placebo. School of Dentistry of USC, Los Angeles, California, USA; Email: [email protected].
    [Show full text]
  • Tinea Versicolor Mimicking Pityriasis Rubra Pilaris
    Tinea Versicolor Mimicking Pityriasis Rubra Pilaris Capt Matthew J. Darling, MC, USAF; CPT Matthew C. Lambiase, MC, USA; Capt R. John Young, MC, USAF Tinea versicolor is a common noninvasive cuta- neous fungal disease. We recount a case of tinea versicolor that mimicked type I (classic adult) pityriasis rubra pilaris. A 54-year-old white man reported a 20-year history of a recurrent pruritic eruption that had marginally improved with use of selenium sulfide shampoo and treatment with oral antihistamines. Results of a skin examination revealed erythematous plaques; islands of spared skin; and follicular erythematous keratotic papules on the trunk, shoulders, and upper arms. A lesion was scraped to obtain skin scales for potassium hydroxide staining. Examination of the stained samples revealed the characteristic “spaghetti and meatballs,” confirming the diagnosis. Cutis. 2005;75:265-267. Case Report A 54-year-old white man presented with a 20-year history of a recurrent pruritic eruption that had marginally improved with use of selenium sulfide shampoo and oral antihistamine therapy. Erythem- atous scaly plaques were noted over the trunk and extremities (Figure 1). Islands of spared skin were most notable on the trunk (Figure 2). Follicular, erythematous, keratotic papules were noted on the shoulders and upper arms (Figure 3). Results of Wood lamp examination revealed a yellow-green Figure 1. Erythematous scaly plaques and islands of fluorescence of the plaques. Results of potassium spared skin on the chest. hydroxide (KOH) staining revealed numerous yeast and hyphae. The patient was diagnosed with tinea versicolor and treated with itraconazole 200 mg/d for 2 weeks.
    [Show full text]
  • Coexistence of Vulgar Psoriasis and Systemic Lupus Erythematosus - Case Report
    doi: http://dx.doi.org/10.11606/issn.1679-9836.v98i1p77-80 Rev Med (São Paulo). 2019 Jan-Feb;98(1):77-80. Coexistence of vulgar psoriasis and systemic lupus erythematosus - case report Coexistência de psoríase vulgar e lúpus eritematoso sistêmico: relato de caso Kaique Picoli Dadalto1, Lívia Grassi Guimarães2, Kayo Cezar Pessini Marchióri3 Dadalto KP, Guimarães LG, Marchióri KCP. Coexistence of vulgar psoriasis and systemic lupus erythematosus - case report / Coexistência de psoríase vulgar e lúpus eritematoso sistêmico: relato de caso. Rev Med (São Paulo). 2019 Jan-Feb;98(1):77-80. ABSTRACT: Psoriasis and Systemic lupus erythematosus (SLE) RESUMO: Psoríase e Lúpus eritematoso sistêmico (LES) são are autoimmune diseases caused by multifactorial etiology, with doenças autoimunes de etiologia multifatorial, com envolvimento involvement of genetic and non-genetic factors. The purpose de fatores genéticos e não genéticos. O objetivo deste relato of this case report is to clearly and succinctly present a rare de caso é expor de maneira clara e sucinta uma associação association of autoimmune pathologies, which, according to some rara de patologias autoimunes, que, de acordo com algumas similar clinical features (arthralgia and cutaneous lesions), may características clínicas semelhantes (artralgia e lesões cutâneas), interfere or delay the diagnosis of its coexistence. In addition, it podem dificultar ou postergar o diagnóstico de sua coexistência. is of paramount importance to the medical community to know about the treatment of this condition, since there is a possibility Além disso, é de suma importância à comunidade médica o of exacerbation or worsening of one or both diseases. The conhecimento a respeito do tratamento desta condição, já que combination of these diseases is very rare, so, the diagnosis existe a possibilidade de exacerbação ou piora de uma, ou de is difficult and the treatment even more delicate, due to the ambas as doenças.
    [Show full text]
  • Juvenile Spondyloarthropathies: Inflammation in Disguise
    PP.qxd:06/15-2 Ped Perspectives 7/25/08 10:49 AM Page 2 APEDIATRIC Volume 17, Number 2 2008 Juvenile Spondyloarthropathieserspective Inflammation in DisguiseP by Evren Akin, M.D. The spondyloarthropathies are a group of inflammatory conditions that involve the spine (sacroiliitis and spondylitis), joints (asymmetric peripheral Case Study arthropathy) and tendons (enthesopathy). The clinical subsets of spondyloarthropathies constitute a wide spectrum, including: • Ankylosing spondylitis What does spondyloarthropathy • Psoriatic arthritis look like in a child? • Reactive arthritis • Inflammatory bowel disease associated with arthritis A 12-year-old boy is actively involved in sports. • Undifferentiated sacroiliitis When his right toe starts to hurt, overuse injury is Depending on the subtype, extra-articular manifestations might involve the eyes, thought to be the cause. The right toe eventually skin, lungs, gastrointestinal tract and heart. The most commonly accepted swells up, and he is referred to a rheumatologist to classification criteria for spondyloarthropathies are from the European evaluate for possible gout. Over the next few Spondyloarthropathy Study Group (ESSG). See Table 1. weeks, his right knee begins hurting as well. At the rheumatologist’s office, arthritis of the right second The juvenile spondyloarthropathies — which are the focus of this article — toe and the right knee is noted. Family history is might be defined as any spondyloarthropathy subtype that is diagnosed before remarkable for back stiffness in the father, which is age 17. It should be noted, however, that adult and juvenile spondyloar- reported as “due to sports participation.” thropathies exist on a continuum. In other words, many children diagnosed with a type of juvenile spondyloarthropathy will eventually fulfill criteria for Antinuclear antibody (ANA) and rheumatoid factor adult spondyloarthropathy.
    [Show full text]
  • Acquired Thrombotic Thrombocytopenic Purpura in a Patient with Pernicious Anemia
    Hindawi Case Reports in Hematology Volume 2017, Article ID 1923607, 4 pages https://doi.org/10.1155/2017/1923607 Case Report Acquired Thrombotic Thrombocytopenic Purpura in a Patient with Pernicious Anemia Ramesh Kumar Pandey, Sumit Dahal, Kamal Fadlalla El Jack Fadlalla, Shambhu Bhagat, and Bikash Bhattarai Interfaith Medical Center, Brooklyn, NY, USA Correspondence should be addressed to Ramesh Kumar Pandey; [email protected] Received 14 January 2017; Revised 2 March 2017; Accepted 23 March 2017; Published 4 April 2017 Academic Editor: Kazunori Nakase Copyright © 2017 Ramesh Kumar Pandey et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Introduction. Acquired thrombotic thrombocytopenic purpura (TTP) has been associated with different autoimmune disorders. However, its association with pernicious anemia is rarely reported. Case Report. A 46-year-old male presented with blood in sputum and urine for one day. The vitals were stable. The physical examination was significant for icterus. Lab tests’ results revealed leukocytosis, macrocytic anemia, severe thrombocytopenia, renal dysfunction, and unconjugated hyperbilirubinemia. He had an elevated LDH, low haptoglobin levels with many schistocytes, nucleated RBCs, and reticulocytes on peripheral smear. Low ADAMTS13 activity (<10%) with elevated ADAMTS13 antibody clinched the diagnosis of severe acquired TTP,and plasmapheresis was started. There was an initial improvement in his hematological markers, which were however not sustained on discontinuation of plasmapheresis. For his refractory TTP, he was resumed on daily plasmapheresis and Rituximab was started. Furthermore, the initial serum Vitamin B12 and reticulocyte index were low in the presence of anti-intrinsic factor antibody.
    [Show full text]
  • Review Anti-Cytokine Biologic Treatment Beyond Anti-TNF in Behçet's Disease
    Review Anti-cytokine biologic treatment beyond anti-TNF in Behçet’s disease A. Arida, P.P. Sfikakis First Department of Propedeutic Internal ABSTRACT and thrombotic complications (1-3). Medicine Laikon Hospital, Athens, Unmet therapeutic needs in Behçet’s Treatment varies according to type and University Medical School, Greece. disease have drawn recent attention to severity of disease manifestations. Cor- Aikaterini Arida, MD biological agents targeting cytokines ticosteroids, interferon-alpha and con- Petros P. Sfikakis, MD other than TNF. The anti-IL-17 anti- ventional immunosuppressive drugs, Please address correspondence to: body secukinumab and the anti-IL-2 such as azathioprine, cyclosporine-A, Petros P. Sfikakis, MD, receptor antibody daclizumab were not cyclophosphamide and methotrexate, First Department of Propedeutic superior to placebo for ocular Behçet’s and Internal Medicine, are used either alone or in combination Laikon Hospital, in randomised controlled trials, com- for vital organ involvement. During the Athens University Medical School, prising 118 and 17 patients, respec- last decade there has been increased use Ag Thoma, 17, tively. The anti-IL-1 agents anakinra of anti-TNF monoclonal antibodies in GR-11527 Athens, Greece. and canakinumab and the anti-IL-6 patients with BD who were refractory E-mail: [email protected] agent tocilizumab were given to iso- to conventional treatment or developed Received on June 7, 2014; accepted in lated refractory disease patients, who life-threatening complications (4, 5). revised form on September 17, 2014. were either anti-TNF naïve (n=9) or Anti-TNF treatment has been shown to Clin Exp Rheumatol 2014; 32 (Suppl. 84): experienced (n=18).
    [Show full text]
  • Presenters: Philip R
    UC Davis Dermatology Online Journal Title Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma Permalink https://escholarship.org/uc/item/8109j4cw Journal Dermatology Online Journal, 20(1) Authors Cohen, Philip R Kurzrock, Razelle Publication Date 2014 DOI 10.5070/D3201021241 License https://creativecommons.org/licenses/by-nc-nd/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Volume 20 Number 1 January 2014 Case Report Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma Philip R. Cohen, MD1 and Razelle Kurzrock, MD2 Dermatology Online Journal 20 (1): 1 1Division of Dermatology, University of California San Diego, San Diego, California; 2Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California San Diego—Moores Cancer Center, La Jolla, California. Correspondence: Philip R. Cohen, MD 10991 Twinleaf Court San Diego, CA 92131-3643 [email protected] Abstract Background: Anakinra is a recombinant form of interleukin-1 receptor antagonist. It is the drug of choice for Schnitzler syndrome and cryopyrin-associated periodic syndromes. It has also recently been demonstrated to have activity in the treatment of the non-Langerhans cell histiocytosis known as Erdheim-Chester disease. Purpose: To describe the activity of anakinra in a patient with co-existing lichen planus and Erdheim-Chester disease. Methods: A 43-year-old woman with progressive Erdheim-Chester disease presented for management of her night sweats and chills, systemic skeletal bone pain, and neurologic (diabetes insipidus) manifestations. She also had widespread cutaneous lichen planus.
    [Show full text]
  • Adult Still's Disease
    44 y/o male who reports severe knee pain with daily fevers and rash. High ESR, CRP add negative RF and ANA on labs. Edward Gillis, DO ? Adult Still’s Disease Frontal view of the hands shows severe radiocarpal and intercarpal joint space narrowing without significant bony productive changes. Joint space narrowing also present at the CMC, MCP and PIP joint spaces. Diffuse osteopenia is also evident. Spot views of the hands after Tc99m-MDP injection correlate with radiographs, showing significantly increased radiotracer uptake in the wrists, CMC, PIP, and to a lesser extent, the DIP joints bilaterally. Tc99m-MDP bone scan shows increased uptake in the right greater than left shoulders, as well as bilaterally symmetric increased radiotracer uptake in the elbows, hands, knees, ankles, and first MTP joints. Note the absence of radiotracer uptake in the hips. Patient had bilateral total hip arthroplasties. Not clearly evident are bilateral shoulder hemiarthroplasties. The increased periprosthetic uptake could signify prosthesis loosening. Adult Stills Disease Imaging Features • Radiographs – Distinctive pattern of diffuse radiocarpal, intercarpal, and carpometacarpal joint space narrowing without productive bony changes. Osseous ankylosis in the wrists common late in the disease. – Joint space narrowing is uniform – May see bony erosions. • Tc99m-MDP Bone Scan – Bilaterally symmetric increased uptake in the small and large joints of the axial and appendicular skeleton. Adult Still’s Disease General Features • Rare systemic inflammatory disease of unknown etiology • 75% have onset between 16 and 35 years • No gender, race, or ethnic predominance • Considered adult continuum of JIA • Triad of high spiking daily fevers with a skin rash and polyarthralgia • Prodromal sore throat is common • Negative RF and ANA Adult Still’s Disease General Features • Most commonly involved joint is the knee • Wrist involved in 74% of cases • In the hands, interphalangeal joints are more commonly affected than the MCP joints.
    [Show full text]
  • Psoriasis and Vitiligo: an Association Or Coincidence?
    igmentar f P y D l o is a o n r r d e u r o s J Solovan C, et al., Pigmentary Disorders 2014, 1:1 Journal of Pigmentary Disorders DOI: 10.4172/jpd.1000106 World Health Academy ISSN: 2376-0427 Letter To Editor Open Access Psoriasis and Vitiligo: An Association or Coincidence? Caius Solovan1, Anca E Chiriac2, Tudor Pinteala2, Liliana Foia2 and Anca Chiriac3* 1University of Medicine and Pharmacy “V Babes” Timisoara, Romania 2University of Medicine and Pharmacy “Gr T Popa” Iasi, Romania 3Apollonia University, Nicolina Medical Center, Iasi, Romania *Corresponding author: Anca Chiriac, Apollonia University, Nicolina Medical Center, Iasi, Romania, Tel: 00-40-721-234-999; E-mail: [email protected] Rec date: April 21, 2014; Acc date: May 23, 2014; Pub date: May 25, 2014 Citation: Solovan C, Chiriac AE, Pinteala T, Foia L, Chiriac A (2014) Psoriasis and Vitiligo: An Association or Coincidence? Pigmentary Disorders 1: 106. doi: 10.4172/ jpd.1000106 Copyright: © 2014 Solovan C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Letter to Editor Dermatitis herpetiformis 1 0.08% Sir, Chronic urticaria 2 0.16% The worldwide occurrence of psoriasis in the general population is Lyell syndrome 1 0.08% about 2–3% and of vitiligo is 0.5-1%. Coexistence of these diseases in the same patient is rarely reported and based on a pathogenesis not Quincke edema 1 0.08% completely understood [1].
    [Show full text]
  • Nasal Septal Perforation: a Novel Clinical Manifestation of Systemic Juvenile Idiopathic Arthritis/Adult Onset Still’S Disease
    Case Report Nasal Septal Perforation: A Novel Clinical Manifestation of Systemic Juvenile Idiopathic Arthritis/Adult Onset Still’s Disease TADEJ AVCIN,ˇ EARL D. SILVERMAN, VITO FORTE, and RAYFEL SCHNEIDER ABSTRACT. Nasal septal perforation has been well recognized in patients with various rheumatic diseases. To our knowledge, this condition has not been reported in children with systemic juvenile idiopathic arthri- tis (SJIA) or patients with adult onset Still’s disease (AOSD). We describe 3 patients with persistent SJIA/AOSD who developed nasal septal perforation during the course of their disease. As illustrat- ed by these cases, nasal septal perforation may develop as a rare complication of SJIA/AOSD and can be considered as part of the clinical spectrum of the disease. In one case the nasal septal perfo- ration was associated with vasculitis. (J Rheumatol 2005;32:2429–31) Key Indexing Terms: SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS ADULT ONSET STILL’S DISEASE NASAL SEPTAL PERFORATION Perforation of the nasal septum has been well recognized in tory manifestations to SJIA and may occur at all ages9. We patients with various rheumatic diseases, including describe 3 patients with persistent SJIA/AOSD who devel- Wegener’s granulomatosis, systemic lupus erythematosus oped nasal septal perforation during the course of their dis- (SLE), and sarcoidosis1,2. Nasal involvement is one of the ease (Table 1). major features of Wegener’s granulomatosis and may lead to massive destruction of the septal cartilage and saddle-nose CASE REPORTS deformity3. Nasal septal perforation is also a recognized Case 1. A 4.5-year-old girl first presented in February 1998 with an 8 week complication of mucosal involvement in SLE and occurs in history of spiking fever, evanescent rash, and polyarthritis.
    [Show full text]
  • Nail Psoriasis and Psoriatic Arthritis for the Dermatologist
    Liu R, Candela BM, English JC. Nail Psoriasis and Psoriatic Arthritis for the Dermatologist. J Dermatol & Skin Sci. 2020;2(1):17-21 Mini-Review Article Open Access Nail Psoriasis and Psoriatic Arthritis for the Dermatologist Rebecca Liu1, Braden M. Candela2, Joseph C English III2* 1University of Pittsburgh School of Medicine 2Department of Dermatology, University of Pittsburgh, Pittsburgh, PA Article Info Abstract Article Notes Psoriatic arthritis (PsA) may affect up to a third of patients with psoriasis. Received: February 16, 2020 It is characterized by diverse clinical phenotypes and as such, is often Accepted: March 17, 2020 underdiagnosed, leading to disease progression and poor outcomes. Nail *Correspondence: psoriasis (NP) has been identified as a risk factor for PsA, given the anatomical Joseph C. English, MD, PhD, University of Pittsburgh Medical connection between the extensor tendon and nail matrix. Therefore, it Center (UPMC), Department of Dermatology, 9000 Brooktree is important for dermatologists to screen patients exhibiting symptoms Rd, Suite 200, Wexford, PA 15090; Email: [email protected]. of NP for joint manifestations. On physical exam, physicians should be evaluating for concurrent skin and nail involvement, enthesitis, dactylitis, ©2020 English JC. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License. and spondyloarthropathy. Imaging modalities, including radiographs and ultrasound, may also be helpful in diagnosis of both nail and joint pathology. Keywords: Physicians should refer to Rheumatology when appropriate. Numerous Nail psoriasis systemic therapies are effective at addressing both NP and PsA including Psoriatic arthritis DMARDs, biologics, and small molecule inhibitors. These treatments ultimately Psoriasis can inhibit the progression of inflammatory disease and control symptoms, Treatment Management thereby improving quality of life for patients.
    [Show full text]
  • The Coexistence of Systemic Lupus Erythematosus and Psoriasis: Is It Possible?
    CASE REPORT The Coexistence of Systemic Lupus Erythematosus and Psoriasis: Is It Possible? Hendra Gunawan, Awalia, Joewono Soeroso Department of Internal Medicine, Faculty of Medicine, Airlangga University - Dr. Soetomo Hospital, Surabaya, Indonesia Corresponding Author: Prof. Joewono Soeroso, MD., M.Sc, PhD. Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Airlangga University - Dr. Soetomo Hospital. Jl. Mayjen. Prof. Dr. Moestopo 4-6, Surabaya 60132, Indonesia. email: [email protected]; [email protected]. ABSTRAK Lupus eritematosus sistemik (LES) adalah penyakit autoimun kronik eksaserbatif dengan manifestasi klinis yang beragam. Psoriasis vulgaris adalah penyakit kulit yang menyerang 1-3% dari populasi. Patofisiologi mengenai tumpang tindihnya penyakit tersebut belum sepenuhnya diketahui. Hal ini menyebabkan adanya tantangan tersendiri dalam tatalaksana kedua penyakit tersebut. Dua orang laki-laki dengan LES dan psoriasis vulgaris dilaporkan dengan manifestasi klinis eritroderma berulang dengan fotosensitif. Perbaikan klinis dicapai setelah terapi kombinasi metilprednisolon dengan metotrexat. Adanya LES yang tumpang tindih psoriasis vulgaris merupakan suatu fenomena klinis yang langka. Hubungan kedua penyakit tersebut dapat berupa saling mendahului atau tumpang tindih pada suatu waktu yang sama dan memiliki hubungan dengan adanya anti- Ro/SSA. Adanya tumpang tindih dari dua penyakit tersebut memberikan paradigma baru dalam patofisiologi, diagnosis, dan tatalaksana di masa mendatang. Kata kunci: lupus eritematosus sistemik, psoriasis vulgaris, psoriatic artritis, overlap syndrome. ABSTRACT Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with various clinical disorders and frequent exacerbations. Psoriasis vulgaris is a common skin disorder which affect 1-3% of general populations. The pathophysiology regarding the coexistence of these diseases is not fully understood. Therapeutic challenges arise since the treatment one of these diseases may aggravate the other.
    [Show full text]